Definitive Contract HHSN272200800042C
Award Date
9/1/08
Potential Completion Date
8/31/13
Potential Value
$26M
Federal Agency
NIAID DEA OA Acquisitions
Awardee
Trius Therapeutics, Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
23
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $3,624,974 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Trius Therapeutics, Inc. for the "DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has a period of performance from September 16, 2013 to September 15, 2015, with a ceiling value of $845,876.06. There is no set-aside for this award....
This is a definitive cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, and Hispanic American-owned small business. The $31,946,661.00 contract provides regulatory affairs support services for the Division of Microbiology and Infectious Diseases (DMID) at NIAID. This includes scientific,...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The $99,299 cost-plus-fixed-fee delivery order was placed under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase I clinical trials for therapeutic products targeting infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics...
This is a federal contract award by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, Hispanic American-owned small business. The contract, valued at $164,128,686.00, is for the NIAID/DAIDS Regulatory Support Center and has an ultimate completion date of April 14, 2031. The contract type is Delivery Order with a Cost Plus Fixed Fee pricing...
This is a $6,335,456.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, and Hispanic American-owned small business. The contract is for regulatory operations support services and has a period of performance through March 30, 2030. TRI has extensive experience supporting...
This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...
This is a $4,469,522.01 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Agile Sciences, Inc., a small disadvantaged business. The contract is for "Targeting Therapeutics Development to Relieve Bottlenecks: Optimizing Lead Therapeutic Compounds Against Infectious Pathogens" and has an ultimate completion date of October 15, 2018. The contract was awarded on June 30, 2015 and was not set aside.
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Utah State University. The contract is for biomedical research and development, with a total potential value of $499,999.00. The contract is a definitive contract with a cost-no-fee pricing type, and has an ultimate completion date of August 30, 2011. The contract is not designated as a set-aside. Without additional details...
This is a $24,457,189.99 cost-plus-award-fee definitive contract awarded to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, Hispanic American-owned small business, by the National Institute of Allergy and Infectious Diseases (NIAID). The contract is for the Regulatory Compliance Center, a set-aside for total small businesses, with a period of performance ending on August 12, 2016. TRI is an experienced provider of comprehensive clinical research support services...
This is a federal contract award to Capital Biosciences, Inc. for "DRUGS AND BIOLOGICALS" with a Firm Fixed Price contract type and ceiling value of $10,000.00. The contract was awarded on December 29, 2011 by the National Institute of Allergy and Infectious Diseases (NIAID), which is a part of the U.S. Department of Health and Human Services (HHS). The contract has an ultimate completion date of January 19, 2012 and was not set aside for any special programs. This appears to be a...